Article
A Phase I, randomized, placebo-controlled, 3-day, ascending-dose study of GS-9451, an NS3/4A protease inhibitor, in genotype 1 hepatitis C patients.
Antiviral therapy - 1 Jan 2013
Lawitz Eric J, Hill John M, Marbury Thomas, Demicco Michael P, Delaney William, Yang Jenny, Moorehead Lisa, Mathias Anita, Mo Hongmei, McHutchison John G, Rodriguez-Torres Maribel, Gordon Stuart C
Abstract excerpt
BACKGROUND: GS-9451 is a novel inhibitor of the HCV NS3/4A protease and demonstrates potent in vitro suppression of HCV genotype 1 replicons. METHODS: The safety, pharmacokinetics and antiviral efficacy of GS-9451 were evaluated in a Phase I study in treatment-naive, HCV genotype-1-infected patients. Patients were randomized to 3 days of once-daily dosing with placebo (n=8) or GS-9451 60 mg (n=8 genotype 1a), 200...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.